NASDAQ:OCUL Ocular Therapeutix Q3 2026 Earnings Date & Estimates $6.82 +0.09 (+1.34%) Closing price 11/3/2026 04:00 PM EasternExtended Trading$7.00 +0.18 (+2.58%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Ocular Therapeutix is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Ocular Therapeutix in Q3 2026Ocular Therapeutix is expected to post earnings of -$0.3635 per share on revenue of $14.27 million. In the same quarter a year earlier Ocular Therapeutix reported -$0.37 per share on revenue of $14.54 million. Ocular Therapeutix last reported on August 3, 2026, posting -$0.35 per share and beating the -$0.3955 consensus estimate. Ocular Therapeutix has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.3635Expected Revenue$14.27 millionPrior-Year EPS-$0.37Prior-Year Revenue$14.54 millionExpected Revenue Growth-1.9%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.35 (Beat by +$0.0455)Last Quarter Revenue$13.48 millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ4 2025 Earnings ReportQ3 2025 Earnings Report Ocular Therapeutix Q3 2026 Earnings FAQ When does Ocular Therapeutix report Q3 2026 earnings? Ocular Therapeutix (NASDAQ:OCUL) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Ocular Therapeutix's Q3 2026 earnings call? Ocular Therapeutix's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Ocular Therapeutix? Analysts expect Ocular Therapeutix to post earnings of -$0.3635 per share for Q3 2026. How much revenue is Ocular Therapeutix expected to report? The consensus revenue estimate for Ocular Therapeutix is $14.27 million for Q3 2026. Ocular Therapeutix Earnings HeadlinesOcular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026November 2 at 7:11 AM | markets.businessinsider.comOcular Therapeutix (OCUL) Set to Announce Quarterly Earnings on TuesdayNovember 2 at 2:26 AM | americanbankingnews.comU.S. Army Advances 75-Year Rare Earth Deal With Nasdaq FirmThe Pentagon is moving to cut US dependence on Chinese rare earth metals, and a Nasdaq-listed company just signed a term sheet for a potential 75-year agreement with the US Army. The proposed deal would let the company build and operate a rare earth processing facility on an active military base, with the Army getting first right to production. New Pentagon restrictions on Chinese-origin rare earth magnets take effect January 1, 2027. The company's mine-to-magnet platform covers feedstock agreements, processing, metallization, and downstream manufacturing, with commercial output targeted for 2027. | The Tomorrow Investor (Ad)Ocular Therapeutix™ to Participate in November Investor and Scientific ConferencesOctober 29, 2026 | globenewswire.comOcular Therapeutix: The Drug Won, The Stock Lost, And That's The OpportunityOctober 25, 2026 | seekingalpha.comTranscript : Ocular Therapeutix, Inc. - Special CallOctober 23, 2026 | marketscreener.comMSee More Ocular Therapeutix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ocular Therapeutix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocular Therapeutix and other key companies, straight to your email. Email Address About Ocular TherapeutixOcular Therapeutix (NASDAQ:OCUL) (NASDAQ:OCUL) is a biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company uses its proprietary hydrogel-based drug-delivery technology to provide sustained or controlled release of medicines in ophthalmic applications. Its commercial products include Dextenza, a dexamethasone ophthalmic insert used to treat ocular inflammation and itching following ophthalmic surgery, and Yutiq, a fluocinolone acetonide intravitreal implant indicated for the treatment of chronic noninfectious posterior uveitis. These products are marketed in the United States. Ocular Therapeutix also develops investigational treatments for retinal and other eye diseases, including sustained-release implant programs designed to deliver medicines directly to the eye. The company was founded in 2006 and is headquartered in Bedford, Massachusetts. Antony Mattessich serves as its president and chief executive officer.View Ocular Therapeutix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marriott's Earnings Beat Shows Why It's More Than a Bet on Travel DemandPalantir's $2.3 Billion Quarter Puts Its Premium Valuation to the TestApple's Earnings Beat Comes With a Catch for Investors Heading Into the HolidaysRepublic Services Has the Momentum, But Waste Management Has Another AdvantageAre the Fears Around Alphabet’s Search Slowdown Warranted?Alphabet's Golden Dome Talks Could Open a New Market, But How Much Is at Stake?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings Beat Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)Devon Energy (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
